Acquisition Synergy ReachBio is now part of Discovery Life Sciences, enabling cross-sell opportunities for biospecimens, biomarkers, and expanded cell based assay capabilities across drug development programs and life science research.

Hematopoietic Focus Specialized primary hematopoietic cell systems and thrombocytopenia risk assays position ReachBio to support predictive toxicology and safety testing, aligned with pharma development pipelines.

Platform Growth History of scalable platforms such as cellPrism and HbF drug screening demonstrates repeatable service offerings that can be packaged and expanded for Discovery's client base.

Marketing and CRM With HubSpot and Leadfeeder in use, ReachBio already has inbound and account based marketing capabilities; leverage Discovery's larger marketing reach to accelerate opportunities in cell biology, biomarker testing, and assay development.

Niche Positioning As a boutique specialist with deep primary cell expertise and a focused service mix, ReachBio provides agility for niche projects in assay development, biomarker integration, and cell bank services that complement larger CROs.